Navigation Links
At Six Months Post-Launch, Neurologist-Reported Patient Share for Tecfidera Among Relapsing-Remitting Multiple Sclerosis Patients Already Rivals that of Gilenya
Date:12/10/2013

EXTON, Pa., Dec. 10, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that neurologist-reported patient share for Biogen Idec's Tecfidera, the newest oral disease-modifying therapy (DMT) to reach the multiple sclerosis (MS) market, has increased significantly to seven percent among DMT-treated relapsing-remitting MS (RR-MS) patients, compared with one and three months post-launch. At six months post-launch, Tecfidera's patient share already matches that of Novartis's Gilenya, the first oral DMT (which became commercially available three years ago) and surpasses that of Genzyme's Aubagio, the second oral DMT, which launched one year ago. This growth in Tecfidera's patient share is driven by significant growth in volume per prescriber, reflecting widening adoption within individual practices, as well as significant expansion of the prescriber base (80 percent of surveyed neurologists). Patient origination data show a trend towards fewer patients initiating Tecfidera therapy following a treatment gap of two or more months, suggesting that most patients warehoused in anticipation of Tecfidera's launch have already been switched to the therapy at six months post-launch.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

The recently published LaunchTrends: Tecfidera (Wave 3) US 2013 report finds that one-fifth of Tecfidera-treated patients have experienced flushing and/or gastrointestinal events according to prescribers, significantly fewer than three months ago. This decrease is likely the result of increased physician and patient experience with the product, allowing for better management of potential side effects. However, tolerability issues continue to be the most common reason for Tecfidera discontinuation, as findings suggest that gastrointestinal events are more disruptive to treatment than flushing. Additionally, prescribers report that significantly more patients discontinued Tecfidera due to cost issues compared with three months ago. Neurologists continue to identify cost and managed care issues among the main obstacles to using Tecfidera more, potentially driven by the significant increase in Tecfidera prescription denials by managed care companies for treatment-naive and switched patients. During qualitative interviews, neurologists, while identifying treatment-naive patients among the most likely candidates for Tecfidera, often reported difficulty getting Tecfidera approved as a first-line agent.

"Even with potential access issues, uptake among current nonprescribers and continued use among prescribers will help drive significant growth in Tecfidera patient share to a forecasted 18 percent over the next six months,"  said BioTrends Research Group Senior Business Insights Analyst Emma Williams, Ph.D. "Together with the slight, yet significant, increase in patient shares for Aubagio and Gilenya, oral DMT share is expected to expand to one-third of the market, stealing share from the platform mainstays including Biogen Idec's Avonex, Bayer HealthCare's Betaseron, Teva's Copaxone, and Pfizer/EMD Serono's Rebif, signaling the evolution of the MS treatment algorithm away from injectable drugs."

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
2. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
3. New silk technology preserves heat-sensitive drugs for months without refrigeration
4. Verenium Reports Financial Results For The Second Quarter And Six Months Ended June 30, 2012
5. Origin Agritech Limited Reports Unaudited Third Quarter Financial Results For Three Months Ended June 30, 2012
6. Insmed Announces Financial Results For Second Quarter And Six-months Ended June 30, 2012
7. New technology delivers sustained release of drugs for up to 6 months
8. Cord Blood America Announces 3rd Quarter and Nine Months 2012 Financial Results
9. Origin Agritech Limited Reports Unaudited First Quarter Financial Results For Three Months Ended December 31, 2012
10. Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
11. China Cord Blood Corporation to Report Third Quarter and First Nine Months of Fiscal 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, ... after being treated for breast cancer benefitted from an injection of stem cells derived ... debilitating, frequent side effect of cancer treatment. , Lymphedema refers to the ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... the trading session at 4,833.32, down 0.22%; the Dow Jones ... the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ... BIND Therapeutics Inc. (NASDAQ: BIND ). Learn more ...
(Date:6/23/2016)... SAN FRANCISCO , June 22, 2016  Amgen ... platinum sponsorship of the QB3@953 life sciences ... improve human health. The shared laboratory space at QB3@953 ... startups overcome a key obstacle for many early stage ... As part of the sponsorship, Amgen launched two "Amgen ...
Breaking Biology Technology:
(Date:6/20/2016)... , June 20, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... prisons involved, it has secured the final acceptance ... facilities for Managed Access Systems (MAS) installed. Furthermore, ... facilities to be installed by October, 2016. MAS ...
(Date:6/9/2016)... Finland , June 9, 2016 ... National Police deploy Teleste,s video security solution to ensure the ... France during the major tournament ... data communications systems and services, announced today that its video ... Prefecture to back up public safety across the ...
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
Breaking Biology News(10 mins):